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Choriocarcinoma, a nonseminomatous germ cell tumor, is a rare type of testicular malignancy that tends to occur in young males.
It is, however, exceedingly rare for choriocarcinoma to involve the GI tract. In this article, we present a rare case of a 31-year-
old male, diagnosed with choriocarcinoma of the left testes, along with several metastases to distant sites. The patient presented
with headaches and severe lower GI bleeding due to metastases to the GI tract, which was eventually controlled with systemic
chemotherapy, while requiring several units of packed RBCs during his admission to the hospital. An extensive literature review
found very few cases of the occurrence of GI bleeding as a consequence of choriocarcinoma due to metastases to the GI tract.
1. Introduction
Testicular cancers are a rare type of cancer but are unique in
the sense that they are largely curable. In 2014, there were
approximately 8,820 new cases of testicular cancer in the
USA [1], with peak incidence between 20 and 34 years of
age [2]. Testicular carcinoma most commonly presents as a
painless testicular mass. However, approximately 20% to 40%
of patients with primary testicular cancer present with pain,
swelling, hardness of the testicle, or a combination of these
symptoms [3].
A type of testicular cancer that is of particular concern
is choriocarcinoma, given that it often appears with diffuse
metastatic disease and progresses very quickly [2]. Testicu-
lar choriocarcinoma is a rare, nonseminomatous germ cell
tumor that represents less than 1% of testicular neoplasms
and presents as a rapidly growing and aggressive tumor of
young males. Notably, the disease is metastatic in nearly half
of patients at the time of diagnosis [4]. Choriocarcinomas dis-
seminate via blood and lymphatics with early hematogenous
dissemination to lungs, liver, brain, and other visceral sites.
Because the average diagnostic delay is 4 to 6 months after
symptomonset, patients often present initially with acute dis-
orders resulting from hemorrhage or necrosis of the primary
tumors or theirmetastases [5]. Delayed treatment contributes
to increased mortality and morbidity [2]. Although chorio-
carcinoma was one of the first malignancies for which treat-
ments and complete cure were accomplished with aggressive
chemotherapy, the outcomes for metastatic choriocarcinoma
remain guarded [2].
In this case report, we will discuss a case of choriocarci-
noma in a patient who presented with extensive metastatic
disease, notably involving the GI tract. We will review his
presentation and imaging, and we will discuss the particular
challenges faced when treating this patient.
2. Case Presentation
A 31-year-old male with past medical history of asthma
presented with headache, melena, and nonbloody nonbil-
ious vomiting, 30 pound (13.6 kg) weight loss, and painful
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Figure 1: Ultrasound of the L testicle, revealing a heterogeneous
infiltrating solid mass.
Figure 2: CT of the chest, revealing extensive metastatic disease
with numerous pulmonary nodular masses and bilateral pleural
effusions.
left-sided testicular mass. Patient was found to be anemic
with a hemoglobin of 7.0 g/dL (Ref.: 13.5–17.5 g/dL) on admis-
sion. Computed Tomography (CT) of head done at the time
of admission showed no acute intracranial abnormalities
and minimal paranasal sinus disease. Ultrasound (US) of
the scrotum showed near completely infiltrated left testicle
highly concerning for a malignancy (Figure 1). Due to rising
concerns of metastatic disease a CT of chest, abdomen, and
pelvis was done. Imaging revealed metastatic lesions to the
lungs (Figure 2) and liver (Figure 3) and a left testicular mass.
Further investigations revealed that beta-HCGwas 217,671 IU
(Ref.: 0–3mIU/mL), Alpha Fetoprotein 2.5 ng/mL (Ref.:
<9.0 ng/dL), Estradiol 760 (Ref.: 20–47 pg/mL), and lactate
dehydrogenase (LDH) 370U/L (Ref.: 91–180U/L). Magnetic
Resonance Imaging (MRI) was also done 4 days after admis-
sion due to patient’s recurrent headaches and was consistent
with late subacute lacunar infarct, but there were no findings
suggestive of metastatic disease. CT angiogram was subse-
quently done due to persistent headaches, and this did show
metastatic disease involving the subcortical white matter. An
echocardiogram was also done that showed likely metastasis
in the left ventricle.
The patient subsequently had two endoscopies to evaluate
for a GI source of bleeding. He was noted to have duo-
denitis, while a follow-up colonoscopy was within normal
limits. Capsular endoscopy performed during the admission
showed actively bleeding lesions in the distal small intestine.
Radiology guided embolization of the actively bleeding sites
was deemed not to be feasible. A biopsy of lung lesion, in
Figure 3: CT of the abdomen, revealing a single hypodense lesion
with irregular foci and wall thickening in the right hepatic lobe.
Hemoglobin over course of admission
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Figure 4: Hemoglobin concentration through patient’s admission.
The first day of chemotherapy coincides with 2/25. The last day of
transfusion was 3/3.
the meantime, confirmed metastatic nonseminomatous tes-
ticular cancer.
The patient was initiated on chemotherapy on day 14 of
his admission with cisplatin, bleomycin, and etoposide with
the intent to control the bleeding primarily, as well as overall
tumor burden. Patient received a total of 18 blood transfu-
sions over a 19-day period. During this time his hemoglobin
concentration continued to fluctuate between 6.5 and 11
(Figure 4). He received his last transfusion 14 days prior
to discharge and 6 days after start of chemotherapy. His
hemoglobin levels remained on average above 10 g/dL sev-
eral days before discharge, suggesting adequate control of
metastases involving the gastrointestinal tract. In addition
a repeat MRI two weeks after admission was noted to have
interval hemorrhagic andnonhemorrhagicmetastaseswithin
the bilateral parietal lobes (Figure 5), left occipital lobe, and
right lateral eye. Ophthalmology was consulted and recom-
mended outpatient follow-upwithout the need for immediate
interventions. Palliative XRT to the brain, although initially
considered, was deferred, since the patient had a relatively
small tumor burden involving his brain and was significantly
symptomatic from GI bleeding.
At the time of discharge patient had received 1 cycle of
chemotherapy and was to receive a total of 4. He recovered
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Figure 5: MRI of the brain revealing new interval hemorrhagic and nonhemorrhagic metastases within the bilateral parietal lobes and left
occipital lobe visible on T2 FLAIR. This was found after starting chemotherapy with 4 cycles of bleomycin, etoposide, and cisplatin.
from his neutropenia and his pain and headaches were
significantly improved.MRI done twomonths after discharge
showed favorable treatment response with no definite new
or residual enhancing lesions and his hemoglobin remained
above 10 g/dL.
3. Discussion
We report the rare clinical presentation of a metastatic testic-
ular choriocarcinoma involving the small bowel, diagnosed
after an episode of lower gastrointestinal bleeding and severe
headaches. Upon diagnosis, the patient was found to have
disseminated disease to the liver, lungs, heart, and brain.
In the setting of testicular choriocarcinoma, metastasis to
the gastrointestinal tract is exceedingly rare. Around 0.95%
to 5% of the cases present in the small bowel, the duodenum
being themost usual site followed by the esophagus, stomach,
and colon [6]. Within this group of patients, the most
common symptom is hemorrhage presenting as melena or
hematemesis. On physical examination, signs of anemia,
such as orthostatic hypotension and pale conjunctiva, can be
identified in some patients.
In regard to staging and treatment, the patient was
diagnosed as having stage IIIC disease, given the presence of
visceral metastases involving the liver and brain, and was cat-
egorized as a poor-risk patient. The standard chemotherapy
regimen for poor-risk patients is 4 cycles of BEP (bleomycin,
etoposide, and cisplatin). However, it should be noted that
between 20% and 30% of poor-risk patients are not cured
with conventional cisplatin-based therapy and less than one-
half experience a durable complete response [7].
The patient presented in this case report was admitted
with severe gastrointestinal bleeding. Initial surgical manage-
ment of the intestinal metastatic lesion was deferred because
of the identification of multiple sites of metastases, including
the lungs and the brain. Systemic chemotherapy was imme-
diately started to control the bleeding while managing the
other metastatic foci. Radiation therapy to the brain was also
delayed because diffuse metastatic GI disease was considered
to be the most life-threatening finding in this patient, as
compared to the relatively small secondary brain lesions not
accompanied by signs suggestive of increased intracranial
pressure and impending herniation (lack of papilledema, no
signs of ventricular shifts). The headaches may have been
attributable to evolving metastatic disease, as evidenced by a
subsequent MRI, while the nausea and vomiting were likely
secondary to metastatic involvement of the gastrointestinal
tract. The GI bleeding ceased during the first cycle of
chemotherapy, an important clinical course adding to the effi-
cacy of chemotherapy inmanaging systemic disease as well as
acute complications of bowel metastases.
The patient was closely monitored for the early detection
of treatment complications. The start of chemotherapy can
complicate the course of the disease by the development of
a very rare, life-threatening syndrome called the choriocarci-
noma syndrome, which is characterized by hemorrhage into
the metastatic sites accompanied by a significant rise in beta-
HCG levels [4]. Given the extent of the disease spread and
its aggressive nature, tumor lysis syndrome was a concern
as documented cases in the literature were found. However,
in this patient, no laboratory or clinical evidence of tumor
lysis syndrome was noted. Given the cardiac involvement in
this patient, the team was concerned about the development
of life-threatening cardiac arrhythmias and embolic cerebral
ischemia; however, these complications were luckily avoided
during the first round of chemotherapy. The only neurologic
symptom that was noted was severe headache that was
attributed to the brain metastases and no focal deficits
appeared during his hospital stay.
In conclusion, our patient was diagnosed with diffuse
metastatic testicular choriocarcinoma that presented with
acute gastrointestinal hemorrhage complicated by anemia.
However, the therapeutic priority was to address the dis-
seminated disease rather than the localized secondary small
bowel lesions or that of his brain disease. The patient was
treated with transfusions of packed red blood cells (pRBCs)
and the chemotherapy proved efficient in controlling the
gastrointestinal hemorrhage while controlling extraintestinal
metastatic disease.
This case highlights the importance of considering the
rare possibility of a metastatic testicular cancer in a young
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male patient presenting with acute gastrointestinal bleeding.
The management should be based on aggressive chemother-
apy with a curative intent.
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